<div id="readability-page-1"><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Scholar Rock Holding ( (SRRK) ) just unveiled an announcement. On March 3, 2026, Scholar Rock reported fourth-quarter and full-year 2025 results, highlighting rapid progress toward bringing its lead SMA therapy apitegromab to market despite continued losses. The company is positioning itself as a key player in neuromuscular diseases through an SMA-focused commercial build-out, expanded manufacturing plans, and advancement of its broader myostatin-based pipeline. Scholar Rock expects to resubmit apitegromab’s Biologics License Application in the U.S. in 2026 following a successful FDA reinspection of Novo Nordisk’s Catalent Indiana site and is preparing for a potential U.S. launch that year, while a European regulatory decision is anticipated in mid-2026 with a planned launch starting in Germany in the second half. The firm continues to advance the Phase 2 OPAL trial in very young SMA patients, develop a subcutaneous formulation of apitegromab, ready an FSHD Phase 2 trial for mid-2026, and dose volunteers in a Phase 1 study of SRK-439. To support commercialization and pipeline development, Scholar Rock secured a new debt facility of up to $550 million from funds managed by Blue Owl Capital, replacing its prior Oxford Finance debt and providing staged access to additional capital tied in part to apitegromab’s regulatory milestones. As of December 31, 2025, the company held $367.6 million in cash, cash equivalents and marketable securities, but reported a larger net loss of $91.0 million in the fourth quarter and $377.9 million for the full year, reflecting ongoing R&amp;D and ramping general and administrative expenses without any product revenue. The most recent analyst rating on (SRRK) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Scholar Rock Holding stock, see the SRRK Stock Forecast page. Spark’s Take on SRRK Stock According to Spark, TipRanks’ AI Analyst, SRRK is a Neutral. SRRK scores mid-range primarily due to very weak financial performance (widening losses, substantial cash burn, and no recent revenue) despite a balance-sheet cushion. The earnings call adds support via runway into 2027 and strong clinical results, but regulatory delay risk remains significant. Technicals are mixed, and valuation is constrained by negative earnings and no dividend. To see Spark’s full report on SRRK stock, click here. More about Scholar Rock Holding Scholar Rock Holding Corp., listed on Nasdaq as SRRK, is a Cambridge, Mass.-based global biopharmaceutical company focused on rare, severe neuromuscular diseases, particularly spinal muscular atrophy. Leveraging a platform in myostatin biology, its lead asset apitegromab is a first-in-class, muscle-targeted monoclonal antibody, with additional programs including an SMA pipeline expansion, an FSHD program and the myostatin inhibitor SRK-439. The company is preparing for commercialization in the U.S. and Europe, building out commercial infrastructure, strengthening manufacturing capacity with multiple fill-finish sites, and funding its growth with a sizable non-dilutive debt facility. Its strategy targets musculoskeletal health in niche, high-need markets, aiming to convert late-stage clinical success into a durable revenue base despite currently operating without product revenue. Average Trading Volume: 1,043,003 Technical Sentiment Signal: Strong Buy Current Market Cap: $4.44B Learn more about SRRK stock on TipRanks’ Stock Analysis page.</div>

Scholar Rock Holding (SRRK) is advancing its lead therapy, apitegromab, for spinal muscular atrophy (SMA) towards a commercial launch, with a U.S. Biologics License Application resubmission expected in 2026. The company reported a net loss of $91 million in Q4 2025 and $377.9 million for the year, while securing a $550 million debt facility to support its commercialization efforts. Despite ongoing losses, analysts rate SRRK stock as a Buy with a $55 price target, although concerns about regulatory delays and financial performance persist.

Tip Ranks

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Scholar Rock

iShares Global Healthcare

iShares US Pharma

ALPS Medical Breakthrough

VG Health

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Health Care Select Sector SPDR

Scholar Rock Advances Apitegromab Toward SMA Commercial Launch